Plans for over the counter prescription drugs criticised
Moves to make more prescription drugs available over the counter criticised
Also In The News
|
Directed by Darren Aronofsky, out January 16th in cinemas, starring Mickey Rourke, Marisa Tomei and Evan Rachel Wood, 100 mins. |  |
Wednesday, 14, Jan 2009 08:31
Government plans to make certain prescription-only drugs available over the counter have been heavily criticised by healthcare professionals.
In a survey published by the Drug and Therapeutics Bulletin (DTB) today the experts suggest drugs companies, rather than patients, have the most to gain from the proposed changes.
The drugs regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), is currently considering whether to make trimethoprim and tamsulosin (Flomax) available over the counter.
Trimethoprim is an antibiotic, commonly used to treat women with symptoms of the urinary infection cystitis, while tamsulosin is prescribed for urinary symptoms related to an enlarged prostate gland (benign prostatic hyperplasia).
Almost two-thirds of those surveyed felt the move to make trimethoprim available in pharmacies without prescription was a bad idea.
And just over half felt that patients might misdiagnose their symptoms, while 51 per cent thought over the counter availability might encourage patients to overuse or misuse the drug.
The proposal to make tamsulosin available without prescription was also rejected by four out of five respondents.
A large number of those surveyed expressed concern that changes in drug availability could delay patients seeking help for more serious underlying disease.
Commenting on the survey results, Dr Ike Iheanacho, editor of the Drug and Therapeutics Bulletin, said: "The survey indicates major concerns about proposals to make certain medicines available without prescription.
"Healthcare professionals seem largely unconvinced that these changes would provide net benefits to patients. They are also sceptical about the motives underlying the proposed switches. We believe that the regulator must take such worries seriously."